HR HPV, HIV and cytology results at baseline and first follow-up
| Baseline | First follow-up | |||||
| Total (n=4043) | Total (n=3074) | |||||
| HPV | n | % | (95% CI) | n | % | (95% CI) |
| Positive | 696 | 17.2 | (0.16 to 0.18) | 438 | 14.3 | (0.13 to 0.16) |
| Negative | 2951 | 73 | (0.72 to 0.74) | 2595 | 84.4 | (0.83 to 0.86) |
| Missing | 396 | 9.8 | (0.09 to 0.1) | 41 | 1.3 | (0.01 to 0.02) |
| HIV | ||||||
| Positive | 718 | 17.8 | (0.17 to 0.19) | 552 | 18 | (0.17 to 0.2) |
| Negative | 3325 | 82.2 | (0.81 to 0.83) | 2522 | 82 | (0.80 to 0.83) |
| Cytology | ||||||
| HSIL | 139 | 3.4 | (0.03 to 0.04) | |||
| LSIL | 329 | 8.1 | (0.07 to 0.09) | |||
| Negative | 3548 | 87.8 | (0.87 to 0.89) | |||
| Missing | 27 | 0.7 | (0.00 to 0.01) | |||
HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, high risk; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.